A novel approach for the acute treatment of heart failure

Circulation: Heart Failure

Volumn 6, Issue 6, 2013, Pages 1250-1258

  Sabbah, Hani N ^a   Tocchetti, Carlo Gabriele ^b,e   Wang, Mengjun ^a   Daya, Samantapudi ^b   Gupta, Ramesh C ^a   Tunin, Richard S ^b   Mazhari, Reza ^c   Takimoto, Eiki ^b   Paolocci, Nazareno ^b   Cowart, Douglas ^c   Colucci, Wilson S ^d   Kass, David A ^b  

^a HENRY FORD HOSPITAL   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c Cardioxyl Pharmaceuticals Inc   (United States)

^d BOSTON MEDICAL CENTER   (United States)

^e Clinica Montevergine   (Italy)

Author keywords

Cardiomyopathies; Heart contractility; Humans; Muscle cells; Nitroxyl; Pharmacology; Vasodilator drugs

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATRIAL NATRIURETIC FACTOR; CARDIOVASCULAR AGENT; CXL 1020; CYCLIC AMP DEPENDENT PROTEIN KINASE; GUANYLATE CYCLASE; ISOPRENALINE; PLACEBO; REACTIVE NITROGEN SPECIES; UNCLASSIFIED DRUG; ANTIOXIDANT; FREE RADICAL; NITROGEN OXIDE; NITROXYL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL PRESSURE; ARTICLE; ARTIFICIAL EMBOLISM; CALCIUM TRANSPORT; CARDIOVASCULAR PARAMETERS; CLINICAL TRIAL; COHORT ANALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DOSE TITRATION; ENDSYSTOLIC ELASTANCE; EXPERIMENTAL DOG; HEART EJECTION FRACTION; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HEART FUNCTION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE FILLING PRESSURE; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART MUSCLE OXYGEN CONSUMPTION; HEART PACING; HEART RATE; HEART STROKE VOLUME; HUMAN; ISCHEMIC CARDIOMYOPATHY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTEMIC VASCULAR RESISTANCE; UNSPECIFIED SIDE EFFECT; VASODILATATION; ANIMAL; CARDIOMYOPATHY; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DOG; DOSE RESPONSE; DRUG EFFECT; FEMALE; HEART CONTRACTION; HEART LEFT VENTRICLE FUNCTION; METABOLISM; MUSCLE CELL; PATHOPHYSIOLOGY; PHARMACOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VASODILATOR DRUGS; DRUG EFFECTS;

CARDIOMYOPATHIES; HEART CONTRACTILITY; HUMANS; MUSCLE CELLS; NITROXYL; PHARMACOLOGY; VASODILATOR DRUGS;

ANIMALS; ANTIOXIDANTS; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FREE RADICALS; HEART FAILURE; HUMANS; MALE; MICE; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; NITROGEN OXIDES; STROKE VOLUME; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 84892653976     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.113.000632     Document Type: Article

References (35)

1. Abraham WT, Fonarow GC, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, O?Connor CM, Sun JL, Yancy CW, Young JB; OPTIMIZEHF Investigators and Coordinators. Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). J Am Coll Cardiol. 2008;52:347-356.
2. Oliva F, Mortara A, Cacciatore G, Chinaglia A, Di Lenarda A, Gorini M, Metra M, Senni M, Maggioni AP, Tavazzi L; IN-HF Outcome Investigators. Acute heart failure patient profiles, management and in-hospital outcome: results of the Italian Registry on Heart Failure Outcome. Eur J Heart Fail. 2012;14:1208-1217.
3. Greenberg B. Acute decompensated heart failure - treatments and challenges. Circ J. 2012;76:532-543.
4. Felker GM, Mentz RJ. Diuretics and ultrafiltration in acute decompensated heart failure. J Am Coll Cardiol. 2012;59:2145-2153.
5. Majure DT, Teerlink JR. Update on the management of acute decompensated heart failure. Curr Treat Options Cardiovasc Med. 2011;13:570-585.
6. Hasenfuss G, Teerlink JR. Cardiac inotropes: current agents and future directions. Eur Heart J. 2011;32:1838-1845.
7. Thackray S, Easthaugh J, Freemantle N, Cleland JG. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis. Eur J Heart Fail. 2002;4:515-529.
8. Felker GM, Benza RL, Chandler AB, Leimberger JD, Cuffe MS, Califf RM, Gheorghiade M, O?Connor CM; OPTIME-CHF Investigators. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol. 2003;41:997-1003.
9. Cuffe MS, Califf RM, Adams KF Jr, Benza R, Bourge R, Colucci WS, Massie BM, O?Connor CM, Pina I, Quigg R, Silver MA, Gheorghiade M; Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigators. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. Jama. 2002;287:1541-1547.
10. Malik FI, Hartman JJ, Elias KA, Morgan BP, Rodriguez H, Brejc K, Anderson RL, Sueoka SH, Lee KH, Finer JT, Sakowicz R, Baliga R, Cox DR, Garard M, Godinez G, Kawas R, Kraynack E, Lenzi D, Lu PP, Muci A, Niu C, Qian X, Pierce DW, Pokrovskii M, Suehiro I, Sylvester S, Tochimoto T, Valdez C, Wang W, Katori T, Kass DA, Shen YT, Vatner SF, 3?g/kg/min Morgans DJ. Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science. 2011;331:1439-1443.
11. Gheorghiade M, Blair JE, Filippatos GS, Macarie C, Ruzyllo W, Korewicki J, Bubenek-Turconi SI, Ceracchi M, Bianchetti M, Carminati P, Kremastinos D, Valentini G, Sabbah HN; HORIZON-HF Investigators. Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure. J Am Coll Cardiol. 2008;51:2276-2285.
12. Flores-Santana W, Salmon DJ, Donzelli S, Switzer CH, Basudhar D, Ridnour L, Cheng R, Glynn SA, Paolocci N, Fukuto JM, Miranda KM, Wink DA. The specificity of nitroxyl chemistry is unique among nitrogen oxides in biological systems. Antioxid Redox Signal. 2011;14:1659-1674.
13. Kemp-Harper BK. Nitroxyl (HNO): a novel redox signaling molecule. Antioxid Redox Signal. 2011;14:1609-1613.
14. Dai T, Tian Y, Tocchetti CG, Katori T, Murphy AM, Kass DA, Paolocci N, Gao WD. Nitroxyl increases force development in rat cardiac muscle. J Physiol. 2007;580(pt.3):951-960.
15. Kohr MJ, Kaludercic N, Tocchetti CG, Dong Gao W, Kass DA, Janssen PM, Paolocci N, Ziolo MT. Nitroxyl enhances myocyte Ca2+ transients by exclusively targeting SR Ca2+-cycling. Front Biosci (Elite Ed). 2010;2:614-626.
16. Paolocci N, Katori T, Champion HC, St John ME, Miranda KM, Fukuto JM, Wink DA, Kass DA. Positive inotropic and lusitropic effects of HNO/NO- in failing hearts: independence from beta-adrenergic signaling. Proc Natl Acad Sci U S A. 2003;100:5537-5542.
17. Paolocci N, Saavedra WF, Miranda KM, Martignani C, Isoda T, Hare JM, Espey MG, Fukuto JM, Feelisch M, Wink DA, Kass DA. Nitroxyl anion exerts redox-sensitive positive cardiac inotropy in vivo by calcitonin generelated peptide signaling. Proc Natl Acad Sci U S A. 2001;98:10463-10468.
18. Tocchetti CG, Wang W, Froehlich JP, Huke S, Aon MA, Wilson GM, Di Benedetto G, O?Rourke B, Gao WD, Wink DA, Toscano JP, Zaccolo M, Bers DM, Valdivia HH, Cheng H, Kass DA, Paolocci N. Nitroxyl improves cellular heart function by directly enhancing cardiac sarcoplasmic reticulum Ca2+ cycling. Circ Res. 2007;100:96-104.
19. Lancel S, Zhang J, Evangelista A, Trucillo MP, Tong X, Siwik DA, Cohen RA, Colucci WS. Nitroxyl activates SERCA in cardiac myocytes via glutathiolation of cysteine 674. Circ Res. 2009;104:720-723.
20. Froehlich JP, Mahaney JE, Keceli G, Pavlos CM, Goldstein R, Redwood AJ, Sumbilla C, Lee DI, Tocchetti CG, Kass DA, Paolocci N, Toscano JP. Phospholamban thiols play a central role in activation of the cardiac muscle sarcoplasmic reticulum calcium pump by nitroxyl. Biochemistry. 2008;47:13150-13152.
21. Sivakumaran V, Stanley BA, Tocchetti CG, Ballin JD, Caceres V, Zhou L, Keceli G, Rainer PP, Lee DI, Huke S, Ziolo MT, Kranias EG, Toscano JP, Wilson GM, O?Rourke B, Kass DA, Mahaney JE, Paolocci N. HNO enhances SERCA2a activity and cardiomyocyte function by promoting redox-dependent phospholamban oligomerization. Antioxid Redox Signal. 2013;19:1185-1197.
22. Gao WD, Murray CI, Tian Y, Zhong X, DuMond JF, Shen X, Stanley BA, Foster DB, Wink DA, King SB, Van Eyk JE, Paolocci N. Nitroxyl-mediated disulfide bond formation between cardiac myofilament cysteines enhances contractile function. Circ Res. 2012;111:1002-1011.
23. Andrews KL, Irvine JC, Tare M, Apostolopoulos J, Favaloro JL, Triggle CR, Kemp-Harper BK. A role for nitroxyl (HNO) as an endotheliumderived relaxing and hyperpolarizing factor in resistance arteries. Br J Pharmacol. 2009;157:540-550.
24. Irvine JC, Favaloro JL, Kemp-Harper BK. NO- activates soluble guanylate cyclase and Kv channels to vasodilate resistance arteries. Hypertension. 2003;41:1301-1307.
25. Paolocci N, Wink DA. The shy Angeli and his elusive creature: the HNO route to vasodilation. Am J Physiol Heart Circ Physiol. 2009;296:H1217-H1220.
26. Miranda KM, Dutton AS, Ridnour LA, Foreman CA, Ford E, Paolocci N, Katori T, Tocchetti CG, Mancardi D, Thomas DD, Espey MG, Houk KN, Fukuto JM, Wink DA. Mechanism of aerobic decomposition of Angeli?s salt (sodium trioxodinitrate) at physiological pH. J Am Chem Soc. 2005;127:722-731.
27. Takimoto E, Champion HC, Li M, Ren S, Rodriguez ER, Tavazzi B, Lazzarino G, Paolocci N, Gabrielson KL, Wang Y, Kass DA. Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. J Clin Invest. 2005;115:1221-1231.
28. Sabbah HN, Stein PD, Kono T, Gheorghiade M, Levine TB, Jafri S, Hawkins ET, Goldstein S. A canine model of chronic heart failure produced by multiple sequential coronary microembolizations. Am J Physiol. 1991;260(4 pt 2):H1379-H1384.
29. Sharir T, Feldman MD, Haber H, Feldman AM, Marmor A, Becker LC, Kass DA. Ventricular systolic assessment in patients with dilated cardiomyopathy by preload-adjusted maximal power. Validation and noninvasive application. Circulation. 1994;89:2045-2053.
30. Chandler MP, Stanley WC, Morita H, Suzuki G, Roth BA, Blackburn B, Wolff A, Sabbah HN. Short-term treatment with ranolazine improves mechanical efficiency in dogs with chronic heart failure. Circ Res. 2002;91:278-280.
31. Senzaki H, Kass DA. Analysis of isovolumic relaxation in failing hearts by monoexponential time constants overestimates lusitropic change and load dependence: mechanisms and advantages of alternative logistic fit. Circ Heart Fail. 2010;3:268-276.
32. Haldar SM, Stamler JS. S-nitrosylation: integrator of cardiovascular performance and oxygen delivery. J Clin Invest. 2013;123:101-110.
33. Derbyshire ER, Marletta MA. Structure and regulation of soluble guanylate cyclase. Annu Rev Biochem. 2012;81:533-559.
34. Katori T, Hoover DB, Ardell JL, Helm RH, Belardi DF, Tocchetti CG, Forfia PR, Kass DA, Paolocci N. Calcitonin gene-related peptide in vivo positive inotropy is attributable to regional sympatho-stimulation and is blunted in congestive heart failure. Circ Res. 2005;96:234-243.
35. Sabbah HN, Goldberg AD, Schoels W, Kono T, Webb C, Brachmann J, Goldstein S. Spontaneous and inducible ventricular arrhythmias in a canine model of chronic heart failure: relation to haemodynamics and sympathoadrenergic activation. Eur Heart J. 1992;13:1562-1572.